GLAUKOS CORPORATION

(GKOS)
  Report
Delayed Nyse  -  05/20 04:00:02 pm EDT
39.34 USD   +0.79%
05/20Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
BU
05/17Citigroup Adjusts Glaukos' Price Target to $43 From $58, Maintains Neutral Rating
MT
05/10Stifel Nicolaus Adjusts Price Target for Glaukos to $40 From $55, Maintains Hold Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
38.37(c) 40.87(c) 39.12(c) 39.03(c) 39.34(c) Last
428 769 561 494 510 458 395 395 380 678 Volume
-0.67% +6.52% -4.28% -0.23% +0.79% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 274 M - -
Net income 2022 -71,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -25,5x
Yield 2022 -
Sales 2023 313 M - -
Net income 2023 -77,6 M - -
Net Debt 2023 - - -
P/E ratio 2023 -23,7x
Yield 2023 -
Capitalization 1 861 M 1 861 M -
Capi. / Sales 2022 6,78x
Capi. / Sales 2023 5,95x
Nbr of Employees 727
Free-Float 96,1%
More Financials
Company
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. It is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the... 
More about the company
Ratings of Glaukos Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about GLAUKOS CORPORATION
05/20Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
BU
05/17Citigroup Adjusts Glaukos' Price Target to $43 From $58, Maintains Neutral Rating
MT
05/10Stifel Nicolaus Adjusts Price Target for Glaukos to $40 From $55, Maintains Hold Rating
MT
05/05GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
05/04GLAUKOS : Q1 Earnings Snapshot
AQ
05/04Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Revenue $67.7M, vs. Street Est of ..
MT
05/04Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q1 Loss $-0.38, vs. Street Est of $-0..
MT
05/04TRANSCRIPT : Glaukos Corporation, Q1 2022 Earnings Call, May 04, 2022
CI
05/04GLAUKOS CORP : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
05/04Glaukos Corporation Announces First Quarter 2022 Financial Results
BU
05/04Glaukos Corporation Updates Sales Guidance for the Year 2022
CI
05/04Glaukos Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/21Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Soc..
BU
04/20Glaukos Announces the Release of its 2021 Sustainability Report
BU
04/13Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
BU
More news
News in other languages on GLAUKOS CORPORATION
05/04Earnings Flash (GKOS) GLAUKOS CORPORATION annonce un chiffre d'affaires de 67,7 million..
05/04Glaukos Corporation met à jour ses prévisions de ventes pour l'année 2022
05/04Glaukos Corporation annonce ses résultats pour le premier trimestre clos le 31 mars 202..
03/14Glaukos déclare avoir démarré un programme clinique de phase 2 pour le traitement des m..
03/14Glaukos annonce le début du programme clinique de phase 2 sur la santé de la cornée pou..
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 39,34 $
Average target price 53,25 $
Spread / Average Target 35,4%
EPS Revisions
Managers and Directors
Thomas William Burns Chairman & Chief Executive Officer
Joseph E. Gilliam President & Chief Operating Officer
Alex Thurman Chief Financial Officer & Senior Vice President
Jay L. Katz Chief Medical Officer
David F. Hoffmeister Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GLAUKOS CORPORATION-11.48%1 861
STRYKER CORPORATION-13.15%87 826
SMITH & NEPHEW PLC-1.62%13 812
INSPIRE MEDICAL SYSTEMS, INC.-23.54%4 853
AXONICS, INC.-10.82%2 351
DOUBLE MEDICAL TECHNOLOGY INC.-33.09%2 111